Product Information

ENTRESTO SPRINKLE 15-16 MG PLT is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $11.6279 per EA under NDC 00078123820. Its NADAC has been published 57 times since Jul 23, 2025.

FDA first approved this application on Apr 12, 2024.

The High Outlier badge above means this manufacturer's average price in the Sacubitril and Valsartan market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

ENTRESTO SPRINKLE 15-16 MG PLT

Sacubitril and Valsartan
$11.6279per EA
High Outlier

Strength

15; 16 mg/1; mg/1

NDC

00078123820

Classification

Brand

Dosage Form

PELLET

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

SACUBITRIL; VALSARTAN

Approval Type

New Drug (NDA)

FDA Application

NDA218591

FDA Approved

4/12/2024

On Market Since

4/12/2024

Pharmacological Classes

Angiotensin 2 Receptor Antagonists
Angiotensin 2 Receptor Blocker
Neprilysin Inhibitor
Neprilysin Inhibitors

Price Statistics

The NADAC for ENTRESTO SPRINKLE 15-16 MG PLT has been published 57 times since Jul 23, 2025, and over the history we have for it it has risen 3.0%. The table below summarizes its recorded NADAC range and movement.

Current price$11.6279 per EA
All-time high$11.6485 (Jun 10, 2026)
All-time low$11.2817 (Sep 17, 2025)
52-week high$11.6485
52-week low$11.2817
Median price$11.6184
Average price$11.4781
Largest weekly change+3.0% (Jan 14, 2026)
Weeks tracked57
Tracking sinceJul 23, 2025

Price History

1W

+0.1%

1M

+0.1%

3M

-0.2%

6M

+0.0%

1Y

+3.0%

3Y

N/A

5Y

N/A

All

+3.0%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Sacubitril and Valsartan market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Frequently asked questions

What is the NADAC price of ENTRESTO SPRINKLE 15-16 MG PLT?

The current National Average Drug Acquisition Cost (NADAC) for ENTRESTO SPRINKLE 15-16 MG PLT, manufactured by Novartis Pharmaceuticals Corporation, is $11.6279 per EA (NDC 00078123820), effective Aug 19, 2026.

How has the price of ENTRESTO SPRINKLE 15-16 MG PLT changed over time?

Over the history we have for it, the NADAC for ENTRESTO SPRINKLE 15-16 MG PLT has risen 3.0%. It has been tracked across 57 weekly CMS publications since Jul 23, 2025.

What are the highest and lowest recorded NADAC prices for ENTRESTO SPRINKLE 15-16 MG PLT?

Since Jul 23, 2025, the NADAC for ENTRESTO SPRINKLE 15-16 MG PLT has ranged from a low of $11.2817 (Sep 17, 2025) to a high of $11.6485 (Jun 10, 2026), with a median of $11.6184 per EA.

Are there cheaper alternatives to ENTRESTO SPRINKLE 15-16 MG PLT?

No other NADAC-published product currently shares the active ingredient and strength of ENTRESTO SPRINKLE 15-16 MG PLT in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures ENTRESTO SPRINKLE 15-16 MG PLT?

ENTRESTO SPRINKLE 15-16 MG PLT (NDC 00078123820) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.